JP2005501801A5 - - Google Patents

Download PDF

Info

Publication number
JP2005501801A5
JP2005501801A5 JP2002563882A JP2002563882A JP2005501801A5 JP 2005501801 A5 JP2005501801 A5 JP 2005501801A5 JP 2002563882 A JP2002563882 A JP 2002563882A JP 2002563882 A JP2002563882 A JP 2002563882A JP 2005501801 A5 JP2005501801 A5 JP 2005501801A5
Authority
JP
Japan
Prior art keywords
disease
neurological
formulation
seizure
manifestations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2002563882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005501801A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/003096 external-priority patent/WO2002064085A2/en
Publication of JP2005501801A publication Critical patent/JP2005501801A/ja
Publication of JP2005501801A5 publication Critical patent/JP2005501801A5/ja
Ceased legal-status Critical Current

Links

JP2002563882A 2001-02-02 2002-01-24 フラクトピラノーススルファメートとエリスロポイエチンを含んで成る神経学的機能不全治療 Ceased JP2005501801A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26619401P 2001-02-02 2001-02-02
PCT/US2002/003096 WO2002064085A2 (en) 2001-02-02 2002-01-24 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin

Publications (2)

Publication Number Publication Date
JP2005501801A JP2005501801A (ja) 2005-01-20
JP2005501801A5 true JP2005501801A5 (enExample) 2005-12-22

Family

ID=23013568

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002563882A Ceased JP2005501801A (ja) 2001-02-02 2002-01-24 フラクトピラノーススルファメートとエリスロポイエチンを含んで成る神経学的機能不全治療

Country Status (17)

Country Link
US (2) US6908902B2 (enExample)
EP (1) EP1471871B1 (enExample)
JP (1) JP2005501801A (enExample)
KR (1) KR100896971B1 (enExample)
AT (1) ATE361089T1 (enExample)
CA (1) CA2437333A1 (enExample)
CY (1) CY1106733T1 (enExample)
DE (1) DE60219961T8 (enExample)
DK (1) DK1471871T3 (enExample)
ES (1) ES2284858T3 (enExample)
MX (1) MXPA03006952A (enExample)
NO (1) NO20033440L (enExample)
NZ (1) NZ548578A (enExample)
PT (1) PT1471871E (enExample)
RU (1) RU2317086C2 (enExample)
WO (1) WO2002064085A2 (enExample)
ZA (1) ZA200306818B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
KR100896971B1 (ko) * 2001-02-02 2009-05-14 오르토-맥네일 파마슈티칼, 인코퍼레이티드 프락토피라노오스 설파메이트 및 에리트로포이에틴을포함하는 신경계 기능장애 치료법
US20030060423A1 (en) * 2001-08-30 2003-03-27 Plata-Salaman Carlos R. Co-therapy for the treatment of dementia and associated behavioral manifestations comprising anticonvulsant derivatives and acetylcholinesterase inhibitors
JP2005534650A (ja) * 2002-06-11 2005-11-17 ザ バーナム インスティテュート エリスロポイエチンおよびインスリン様増殖因子の神経保護的相乗作用
US20030235576A1 (en) * 2002-06-15 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg New drug combinations for the treatment of ischaemic conditions
DE10226814A1 (de) * 2002-06-15 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung ischämischer Zustände
EP1815854A1 (en) * 2002-09-17 2007-08-08 Motac Neuroscience Limited Treatment of dyskenesia
ES2286453T3 (es) * 2002-09-17 2007-12-01 Motac Neuroscience Limited Tratamiento de la discinesia.
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
AT500929B1 (de) 2004-11-09 2007-03-15 Medizinische Uni Wien Muw Pharmazeutische zubereitung die erythropoietin enthält
WO2007020922A1 (ja) * 2005-08-17 2007-02-22 Chugai Seiyaku Kabushiki Kaisha 脳疾患の治療剤および予防剤
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
WO2008022349A2 (en) * 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
WO2008088820A2 (en) * 2007-01-16 2008-07-24 The Johns Hopkins University Glutamate receptor antagonists and methods of use
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
RU2335296C1 (ru) * 2007-06-26 2008-10-10 Сергей Марович Дудкин Фармацевтическая композиция для профилактики и лечения неврологических заболеваний
CA2694762A1 (en) 2007-07-27 2009-02-05 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
CA2724841A1 (en) * 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
EP2408474B1 (en) 2009-03-18 2019-06-26 Armagen, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
HUE044865T2 (hu) 2009-10-09 2019-11-28 Armagen Inc Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére
ES2983576T3 (es) 2011-12-02 2024-10-23 Armagen Inc Métodos y composiciones para aumentar la actividad arilsulfatasa en el SNC
US9457008B2 (en) 2012-03-23 2016-10-04 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Joint product comprising synephrine and topiramate
CN102579367B (zh) 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US5242942A (en) 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
JPH09501418A (ja) 1993-07-19 1997-02-10 アムジエン・インコーポレーテツド エアゾル化タンパク質の安定化
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
DE69434652T2 (de) * 1993-12-23 2007-03-01 Ortho-Mcneil Pharmaceutical, Inc. Antikonvulsive pseudofructopyranose sulfamate
IL116085A (en) 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
WO1998000124A1 (en) 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
DE69736780T2 (de) 1996-08-02 2007-09-06 Ortho-Mcneil Pharmaceutical, Inc. Polypeptide mit einzelnem kovalent gebundenen n-terminalen wasserlöslichen polymer
ATE341625T1 (de) 1997-07-23 2006-10-15 Roche Diagnostics Gmbh Herstellung von erythropoietin durch endogene genaktivierung mit viralen promotoren
PT902085E (pt) 1997-09-01 2004-02-27 Aventis Pharma Gmbh Eritropoietina humana recombinante com perfil de glicosilacao vantajoso
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
AU759467B2 (en) * 1998-04-02 2003-04-17 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
AU775422B2 (en) 1998-06-15 2004-07-29 Gtc Biotherapeutics, Inc. Erythropoietin analog-human serum albumin fusion
JP2003521471A (ja) * 1999-04-08 2003-07-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 慢性神経変性疾患を処置することに有用な抗痙攣薬誘導体
PL352223A1 (en) * 1999-04-13 2003-08-11 Kenneth S Warren Inst Modulation of excitable tissue function by peripherally administered erythropoietin
CA2270795A1 (en) * 1999-05-05 2000-11-05 Gestilab Inc. Neuroprotective compositions and uses thereof
KR100896971B1 (ko) * 2001-02-02 2009-05-14 오르토-맥네일 파마슈티칼, 인코퍼레이티드 프락토피라노오스 설파메이트 및 에리트로포이에틴을포함하는 신경계 기능장애 치료법

Similar Documents

Publication Publication Date Title
JP2005501801A5 (enExample)
RU2003124059A (ru) Лечение неврологической дисфункции с применением сульфаматов фруктопиранозы и эритропоэтина
DK1303495T3 (da) Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet
Kurczynski Hyperekplexia
IL157591A (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
HUP9904525A2 (hu) S-(-)-N-Propargil-1-amino-indán tartalmú neurológiai rendellenességek kezelésére alkalmas gyógyszerkészítmények
MX2023009294A (es) Analogos inspirados por oxa-ibogaina para el tratamiento de trastornos neurologicos y psiquiatricos.
JP2004532849A5 (enExample)
JP2004523555A5 (enExample)
Shahar et al. Sporadic major hyperekplexia in neonates and infants: clinical manifestations and outcome
BR0214425A (pt) Compostos carbonilbenzoxazina para aperfeiçoamento de respostas sinápticas glutamatérgicas
Yamanaka et al. Over 10 years of isolated autonomic failure preceding dementia and Parkinsonism in 2 patients with Lewy body disease
Knight The role of primary cilia in cartilage health and disease
GB202418144D0 (en) Antisense oligonucleotides for the treatment of parkinson's disease
Hamidi et al. Contribution of Sensory Systems to Static Balance in Elderly Women following Exercise Training (Part Two: Hippotherapy vs Aquatic Exercise): Quasi-experimental Study
Shim et al. A Clinical Report of Wallenberg's Syndrome
ATE539763T1 (de) Verwendung des nervenwachstumfaktors in augentropfen zur behandlung von erkrankungen des zentralen nervensystems, wie z.b. alzheimer- krankheit und parkinson-krankheit
SU1621927A1 (ru) Устройство дл выт жени позвоночника
Wang Role of Tai Chi in osteoarthritis
Bove et al. 16.3 Postural responses to continuous asymmetric neckmuscle vibrations in patients with cervical dystonia
Avanzino et al. 16.1 Posturographic analysis in patients with essentialtremor
Rahmlow et al. 113. Unusual spinal epidural cyst mimicking Hirayama disease
Yun et al. 112. Spinocerebellar ataxia type 7 with familial trait∗
Nagaratnam et al. Multisystem Atrophy (MSA)